- Home
- HAFN vs GH Comparison
HAFN vs GH Comparison
Compare HAFN & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HAFN | GH |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 14.1B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | HAFN | GH |
|---|---|---|
| Price | $5.30 | $101.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 21 |
| Target Price | $6.50 | ★ $96.48 |
| AVG Volume (30 Days) | 1.2M | ★ 2.0M |
| Earning Date | 12-01-2025 | 10-29-2025 |
| Dividend Yield | ★ 7.51% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $2,221,808,000.00 | $902,569,000.00 |
| Revenue This Year | N/A | $35.00 |
| Revenue Next Year | $0.20 | $26.80 |
| P/E Ratio | $8.61 | ★ N/A |
| Revenue Growth | N/A | ★ 30.38 |
| 52 Week Low | $3.61 | $29.91 |
| 52 Week High | $6.64 | $112.43 |
Technical Indicators
Market Signals| Indicator | HAFN | GH |
|---|---|---|
| Relative Strength Index (RSI) | 27.03 | 54.54 |
| Support Level | $5.51 | $96.28 |
| Resistance Level | $5.40 | $105.01 |
| Average True Range (ATR) | 0.09 | 3.99 |
| MACD | -0.04 | -1.19 |
| Stochastic Oscillator | 4.03 | 40.34 |
Price Performance
Historical ComparisonAbout HAFN Hafnia Limited
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.